- Home
- CIVB vs CTNM Comparison
CIVB vs CTNM Comparison
Compare CIVB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVB
- CTNM
- Stock Information
- Founded
- CIVB 1884
- CTNM 2009
- Country
- CIVB United States
- CTNM United States
- Employees
- CIVB N/A
- CTNM N/A
- Industry
- CIVB Major Banks
- CTNM
- Sector
- CIVB Finance
- CTNM
- Exchange
- CIVB Nasdaq
- CTNM Nasdaq
- Market Cap
- CIVB 402.3M
- CTNM 328.1M
- IPO Year
- CIVB N/A
- CTNM 2024
- Fundamental
- Price
- CIVB $22.19
- CTNM $10.97
- Analyst Decision
- CIVB Buy
- CTNM Strong Buy
- Analyst Count
- CIVB 5
- CTNM 5
- Target Price
- CIVB $25.25
- CTNM $22.20
- AVG Volume (30 Days)
- CIVB 117.7K
- CTNM 102.8K
- Earning Date
- CIVB 10-23-2025
- CTNM 11-10-2025
- Dividend Yield
- CIVB 3.07%
- CTNM N/A
- EPS Growth
- CIVB 33.82
- CTNM N/A
- EPS
- CIVB 2.66
- CTNM N/A
- Revenue
- CIVB $163,095,000.00
- CTNM N/A
- Revenue This Year
- CIVB $17.30
- CTNM N/A
- Revenue Next Year
- CIVB $12.90
- CTNM N/A
- P/E Ratio
- CIVB $8.33
- CTNM N/A
- Revenue Growth
- CIVB 11.59
- CTNM N/A
- 52 Week Low
- CIVB $17.47
- CTNM $3.35
- 52 Week High
- CIVB $25.59
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- CIVB 64.13
- CTNM 47.41
- Support Level
- CIVB $19.84
- CTNM $10.16
- Resistance Level
- CIVB $21.64
- CTNM $11.34
- Average True Range (ATR)
- CIVB 0.72
- CTNM 0.79
- MACD
- CIVB 0.15
- CTNM -0.20
- Stochastic Oscillator
- CIVB 90.38
- CTNM 28.97
About CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.